Accepted
at 8:03 p.m. Nov, 12, 2023
by
TheAnKing
Author:
jaynguyen
Type of change:
Updated Tags
Rationale for change
This section was signifiantly revised in 2nd gen alikhan. I have made new cards for this section. Would consider deleting this card
Before
After
Text
Text
Text
Text
Extra
Both are FDA approved for advanced melanoma; Phase 3 RCTs in patients with advanced melanoma have demonstrated increased overall survival, increased progression-free survival, and fewer side effects with either agent when compared to ipilimumab or conventional chemotherapy (some patients have durable responses even after completion of treatment), efficacy improved when used in combination with ipilimumab (main disadvantage = increased immune-mediated side effects)
Personal Notes
Empty field
Missed Questions
Empty field
DermPath
Empty field
Dermoscopy
Empty field
VisualDx
Empty field
DermNet
Empty field
Full Spectrum of Dermatology
Empty field
Dermnemonics
Empty field
Dermatographix
Empty field
Textbook
Empty field
Additional Resources
Empty field
One by one
Empty field